Compare
DarioHealth Corp. vs Baird Medical Investment Holdings Ltd vs Sonoma Pharmaceuticals, Inc. vs Nephros Inc
| Latest fiscal year | DarioHealth Corp. DRIO | Baird Medical Investment Holdings Ltd BDMD | Sonoma Pharmaceuticals, Inc. SNOA | Nephros Inc NEPH |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-03-31 | 2025-12-31 |
| Revenue | $22.36M | $22.54M | $19.53M | $18.79M |
| Revenue growth (YoY) | -17.3% | -39.2% | +36.7% | +32.7% |
| Gross margin | 56.6% | 83.8% | 38.0% | 61.9% |
| Operating margin | -163.9% | -113.7% | -12.6% | 6.1% |
| Net margin | -186.6% | -122.2% | -16.3% | 6.4% |
| Net income | -$41.71M | -$27.54M | -$3.17M | $1.19M |
| EPS (Diluted) | $10.12 | -$0.98 | -$1.89 | $0.11 |
| Operating cash flow | -$25.94M | -$1.34M | -$3.93M | $1.60M |
| Free cash flow | -$26.08M | -$1.39M | -$4.12M | n/a |
| Cash & equivalents | $21.80M | $178.3K | $2.40M | $5.40M |
| Total assets | $110.08M | $69.70M | $13.96M | $13.64M |
| Total liabilities | n/a | $38.48M | $10.87M | $3.44M |
| Shareholders' equity | $67.92M | $31.22M | $3.10M | $10.20M |
| Return on year-end equity | -61.4% | -88.2% | -102.6% | 11.7% |
| Shares outstanding | 6.91M | 30.75M | 1.80M | 10.64M |
Revenue, most recent five fiscal years
| Fiscal year | DarioHealth Corp. | Baird Medical Investment Holdings Ltd | Sonoma Pharmaceuticals, Inc. | Nephros Inc |
|---|---|---|---|---|
| Latest | $22.36M Ended 2025-12-31 | $22.54M Ended 2025-12-31 | $19.53M Ended 2026-03-31 | $18.79M Ended 2025-12-31 |
| 1 year earlier | $27.04M Ended 2024-12-31 | $37.04M Ended 2024-12-31 | $14.29M Ended 2025-03-31 | $14.16M Ended 2024-12-31 |
| 2 years earlier | $20.35M Ended 2023-12-31 | $31.46M Ended 2023-12-31 | $12.73M Ended 2024-03-31 | $14.24M Ended 2023-12-31 |
| 3 years earlier | $27.66M Ended 2022-12-31 | $35.09M Ended 2022-12-31 | $13.27M Ended 2023-03-31 | $9.97M Ended 2022-12-31 |
| 4 years earlier | $20.51M Ended 2021-12-31 | n/a | $12.63M Ended 2022-03-31 | $10.22M Ended 2021-12-31 |